近日，內(nèi)蒙古醫(yī)科大學(xué)附屬醫(yī)院檢驗(yàn)科鄭文琪課題組閆志老師，使用IPHASE品牌產(chǎn)品：CD4+T 細(xì)胞在《Cytokine》期刊上發(fā)表文章《Diagnostic accuracy and cellular origin of pleural fluid CXCR3 ligands for tuberculous pleural effusion》，影響因子3.8！
 

　　本論文中，評估了 CXCL9 和 CXCL11 對結(jié)核性胸腔積液(TPE)的診斷潛力，并確定了它們在 TPE 發(fā)生過程中的細(xì)胞起源和作用。我們在中國的兩個(gè)中心前瞻性地招募了未確診的胸腔積液患者。我們收集了入院時(shí)的胸腔積液，并測定了 CXCL9 和 CXCL11 的水平。采用 ROC 曲線和 DCA 評估了 CXCL9 和 CXCL11 的診斷準(zhǔn)確性。用卡介苗(Bacillus Calmette-Guérin，BCG)處理 THP-1 細(xì)胞衍生的巨噬細(xì)胞，并采用 qRT-PCR 和 ELISA 方法測定 CXCL9 和 CXCL11。CXCL9和CXCL11對Th細(xì)胞的趨化吸引活性通過透孔試驗(yàn)進(jìn)行了分析。我們發(fā)現(xiàn)胸膜 CXCL9 和 CXCL11 是 TPE 的潛在診斷標(biāo)志物，但其診斷準(zhǔn)確性在老年患者中受到影響。CXCL9 和 CXCL11 可促進(jìn)外周 Th 細(xì)胞向胸膜腔遷移，從而成為治療 TPE 的靶點(diǎn)。
 

　　
 

　　摘要
 

　　Background: Pleural biomarkers represent potential diagnostic tools for tuberculous pleural effusion (TPE) due to their advantages of low cost, short turnaround time, and less invasiveness. This study evaluated the diagnostic
 

　　accuracy of two CXCR3 ligands, C-X-C motif chemokine ligand 9 (CXCL9) and CXCL11, for TPE. In addition, we investigated the cellular origins and biological roles of CXCL9 and CXCL11 in the development of TPE.
 

　　Methods: This double-blind study prospectively enrolled patients with undiagnosed pleural effusion from two centers (Hohhot and Changshu) in China. Pleural fluid on admission was obtained and levels of CXCL9 and CXCL11 were measured by an enzyme-linked immunosorbent assay (ELISA). The receiver operating character-istic (ROC) curve and the decision curve analysis (DCA) were used to evaluate their diagnostic accuracy and net benefit, respectively. THP-1 cell-derived macrophages were treated with Bacillus Calmette-Gu´erin (BCG), and quantitative real-time PCR (qRT-PCR) and ELISA were used to determine the mRNA and protein levels of CXCL9 and CXCL11. The chemoattractant activities of CXCL9 and CXCL11 for T helper (Th) cells were analyzed by a transwell assay.
 

　　Results: One hundred and fifty-three (20 TPEs and 133 non-TPEs) patients were enrolled in the Hohhot Center, and 58 (13 TPEs and 45 non-TPEs) were enrolled in the Changshu Center. In both centers, we observed increased CXCL9 and CXCL11 in TPE patients. The areas under the ROC curves (AUCs) of pleural CXCL9 and CXCL11 in the Hohhot Center were 0.70 (95 % CI: 0.55–0.85) and 0.68 (95 % CI: 0.52-0.84), respectively. In the Changshu Center, the AUCs of CXCL9 and CXCL11 were 0.96 (95 % CI: 0.92–1.00) and 0.97 (95 % CI: 0.94–1.00), respectively. The AUCs of CXCL9 and CXCL11 decreased with the advancement of age. The decision curves of CXCL9 and CXCL11 showed net benefits in both centers. CXCL9 and CXCL11 were upregulated in BCG-treated macrophages. Pleural fluid from TPE and conditioned medium from BCG-treated macrophages were chemotactic for Th cells. Anti-CXCL9 or CXCL11 neutralizing antibodies could partly block the chemotactic activity. Conclusions: Pleural CXCL9 and CXCL11 are potential diagnostic markers for TPE, but their diagnostic accuracy is compromised in elderly patients. CXCL9 and CXCL11 can promote the migration of peripheral Th cells, thus representing a therapeutic target for the treatment of TPE.
 

完整版文獻(xiàn)可在【IPHASE】公眾號后臺留言【獲取文章】
 

　　再次恭喜文獻(xiàn)發(fā)表，以及對我司產(chǎn)品的認(rèn)可，希望以上文獻(xiàn)能幫助大家了解目前研究進(jìn)展及我們的核心技術(shù)，歡迎各位新老客戶聯(lián)系我們咨詢、提出意見，愿我們的努力成果與您的科研碰撞出不一樣的火花！
 

　　
 

　　發(fā)    文    章    得    獎    勵(lì)
 

　　凡使用本公司產(chǎn)品，在國內(nèi)及國際刊物上發(fā)表論文(論文發(fā)表日起一年內(nèi))，并注明產(chǎn)品屬于IPHASE BIOSCIENCES CO,LTD / 匯智和源生物技術(shù)(蘇州)有限公司所有，即可申請獎勵(lì)。根據(jù)發(fā)表刊物影響因子不同，給予不同金額獎品：
 

　　非SCI論文及IF≤5分，500元禮品；
 

　　5分

　　8分

　　IF≥10分 2000元；
 

　　注：禮品卡也可兌換同等金額產(chǎn)品購買抵用券；
 

　　活動多多，禮品豐厚，快來參與吧！
 

　　
 

　　關(guān)    于    我    們
 

　　匯智和源，致力于為創(chuàng)新藥研發(fā)企業(yè)及生命科學(xué)研究機(jī)構(gòu)提供高品質(zhì)的生物試劑，IPHASE為公司核心品牌，品牌宗旨“Innovative Reagents For Innovative Research”。